Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18961118 | 0.83 | KEAP1 (0.31) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL1881404 | 0.77 | NFE2L2 (0.60) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL3022767 | 0.77 | NFE2L2 (0.60) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL14457285 | 0.75 | KEAP1 (0.32) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL1880638 | 0.75 | DGAT1 (0.34) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL13921048 | 0.75 | DGAT1 (0.34) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL23895099 | 0.74 | HCAR2 (0.44) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL5691943 | 0.74 | HCAR2 (0.44) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL4144646 | 0.73 | ALDH1A1 (0.48) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL1884771 | 0.71 | HCAR2 (0.56) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072595-B2 | Benzothiophene-based selective estrogen receptor downregulator compounds | The Board of Trustees of lhe University of Illinois (US) | 2021-07-27 | — | — | US | disclosed |
| US-20170166550-A1 | BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166550-A1 | BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS | ESR1, ESR2, GPER1 | KEAP1 466/4885NFE2L2 100/4885HCAR2 229/4885 |
| US-11072595-B2 | Benzothiophene-based selective estrogen receptor downregulator compounds | ESR1, ESR2, GPER1 | KEAP1 390/4885NFE2L2 83/4885HCAR2 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.